Small Business Owner****Keeping America together
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's understanding what TSOI is doing, most don't
When TSOI starts using JadiCell to heal people the pps will take it's place
with a smaller float we would have a larger jump up but MM's would still take the price down
All restricted shares they are not in the float
People do flip OTC stocks they're in for a quick buck and marketers try to regulate the price, goes down to where they want it to I did have E-Trade for a while in the past didn't care for it still trade with TDA don't care much for the platform either they're always changing them have to do some real Deep D on this company therapeutic Solutions everything is legit
Extended hours is after market for TSOI, OTC does not trade after 4 pm E
The bid and ask looks this way because half the MM's are not on the L2
JadiCell saving lives
I wouldn't be able to put someone like Tim down I believe he is a hard worker things will get accomplished it just takes time good thing I have a day job to keep me busy and not worry about my stock
Last year the 10K was out April 9 was due March 31st
I want TSOI to be long term, would rather not pay tax
going to wait and buy more
supplements are better for you than drugs like heart medication or metformin
it is much better to prevent something than ending up in the hospital
if your in your 50's or 60's you understand you are what you eat
TSOI is headed in the right direction I hope they come out with more supplements
reverse hart disease, and diabetes
no I believe Tim's lawyers told him to stay quite
I don't think so, is Allogen Biologics a public company I don't think so
Allogen Biologics Inc, a wholly owned subsidiary of TSOI
I think we are good
There is a Nexus Between the Claimed Cells, the Ricordi Study
and, the Licenses.
A nexus between the objective evidence and a novel feature of the claimed
invention is presumptively attributed to the patented invention where the product is
coextensive with the claimed features. See Muniauction, Inc. v. Thomson Corp.,
532 F.3d 1318, 1328 (Fed. Cir. 2008). Here, the record demonstrates the claimed
cells were used in the Ricordi Study. See Patel Dec., ¶ 27. In addition, the licenses,
as well as public SEC documents of the Licensees, specifically mention the ’176
Patent as covering the technology used by the Licensees for their operations. Id. ¶
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2021-01535%2F7
The Claimed Cells Have Been Commercially Successful as Shown
by Licenses.
Several sophisticated companies (“the Licensees”) license the ’176 Patent to
harvest cells for different beneficial applications. See Patel Dec., ¶¶ 30–40; see In
re Rouffet, 149 F.3d 1350, 1355 (Fed. Cir. 1998) (objective evidence of
nonobviousness may include commercial success, long-felt but unsolved need, and
licenses showing industry respect). Those licenses were not the result of litigation,
1 In addition to the industry praise in the Ricordi Study, several prominent news
outlets have praised the impressive results achieved by Jadi Cell’s licensees, TSOI
and ImmCelz. See Exs. 2014-2015.
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2021-01535%2F7
so many good things to read about the patent trial in TSOI's team they are brilliant
b. Others Have Tried and Failed to Receive Approval for a Phase III
Trial.
Ricordi identified a potency assay for the claimed cells. See Ricordi Dec.
¶¶ 23–27. Due, at least in part, to that assay, a Phase III clinical trial was approved
by the FDA. Id. Other developers have requested approval to conduct Phase III
trials of their stem cells but been rejected. Id. ¶ 27. And others have tried, but
failed, to develop stem cells that would permit development of a potency assay to
reliably test their stem cells. Id.; see Uniroyal, Inc. v. Rudkin-Wiley Corp., 837
F.2d 1044, 1054 (Fed. Cir. 1988) (“[F]ailure of others to provide a feasible solution
to a long standing problem is probative of nonobviousness.”).
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2021-01535%2F7
Filed on Behalf of Jadi Cell, LLC and Amit Patel
By: Jed Hansen
Thorpe North & Western, LLP
175 S. Main St., Ste. 900
Salt Lake City, UT 84111
Tel: (801) 566-6633
UNITED STATES PATENT AND TRADEMARK OFFICE
_____________
BEFORE THE PATENT TRIAL AND APPEAL BOARD
_____________
Restem, LLC
Petitioner
v.
Jadi Cell, LLC
Patent Owner.
_____________
Patent 9,803,176
_____________
Case IPR 2021-01535
PATENT OWNER PRELIMINARY RESPONSE
Case IPR 2021-01535
Patent 9,803,176
I. INTRODUCTION
The ’176 Patent embodies unique, differentiating cells with never-beforeseen combinations of cellular characteristics. Generally speaking, the ’176 Patent
discloses isolated stem cells derived from a very specific method involving the
subepithelial layer of umbilical cord (“UC”) tissue. The isolated stem cells express
numerous certain cell markers and do not express NANOG and many other cell
markers in a combination that is not only novel and non-obvious, but presents a
ground-breaking alternative to conventional medicine. See, e.g., Ex. 1001, ’176
Patent 8:39–54; id. Abstract; id. at 1:33–36. Indeed, despite the failure of the
planet’s best minds, the inventor, Dr. Patel, discovered cells that help treat COVID,
among other serious diseases. Dr. Patel’s claimed cells are the subject of several
commercial licenses and have been approved for a Phase III clinical trial by the
FDA.
The Petition seeks to invalidate an issued patent that embodies the lifesaving claimed cells. The Petition, however, suffers from several fatal flaws. The
Petition’s primary line of attack involves an assertion of inherency based on
strained and inaccurate (at times cut out of whole cloth) readings of a highly
complex and unpredictable scientific field. Where its inherency arguments fall flat,
Case IPR 2021-01535
Patent 9,803,176
2
the Petition resorts to four, and sometimes five, references in an effort to create all
the recited claim limitations.
Among other problems, Petitioner’s prior art does not disclose all of the
claimed elements. Where elements are disclosed, they are done so in disparate
references only peripherally related to Dr. Patel’s discovery. And while the various
references may disclose some of the recited elements, when looking at the
references as a whole, as is required, they emphasize three important facts: (1) the
not all of the elements are disclosed, (2) the art is highly unpredictable, and (3) the
POSITA would not be motivated to combine the references. For these reasons and
those articulated further herein, the Petition should be denied.
Frank is letting us buy all the cheap shares
At least TSOI has many other things going for them
Just going to sit and wait see what happens
I was looking under USPTO it wouldn't come up last night
got it today
Restem https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,778,679.PN.&OS=PN/8,778,679&RS=PN/8,778,679
TSOI Amit Patel
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9803176.PN.&OS=PN/9803176&RS=PN/9803176
If you have the patent number I can then look it up thanks
it's a petition, the CEO could clear things up for us hopefully we are near the end of the petition
I believe something as big as our patent and JadiCell someone will try to make it not happen because of greed
for me saving lives is more important
I have been reading the Restem LLC v Amit Patel this is a petition I believe this has not gone to court It’s Restem trying to stop TSOI from
Going to phase 3 with Use of UC-MSCs for COVID-19 Patients
Restem has something similar, and they do not have a patent, Restem only has a patent application
TSOI has a patent with Amit Patel and we have been approved by the FDA to go ahead with phase 3
I believe Restem is stating our patent is flawed, we have already disputed that restem’s application is flawed.
Maybe this will get us noticed it’s taking too long, all the lives that could have been saved.
All the efforts from our doctors being put into JadiCell I commend everyone working with TSOI
Restem doesn't even have a patent they have a patent application and it hasn't even been approved
They are trying to steal what we already have
well the FDA approved phase 3 already
As far as what I read in the dispute last night the stem cells are not exactly the same
Does anyone know if restem has a patent on their stem cells
I found this last night first heard of it yesterday afternoon won't be able to check it out till tomorrow busy working but I see tsoi have a few people taking care of this
Driving home I was thinking about TSOI and what I'm holding and thinking I should get more before they turn GOLDEN
Does anyone live in California to see Frank's EV cars?
WE have a product and a great one with QUADRAMUNE PPs should be higher TSOI
WE have some volume XSPT
Nice day Stem Cells not far away
reviews on Amazon look great https://www.amazon.com/product-reviews/B08XLQX3CF
Patents are very important, MM's should be taking this up
more investors will be entering
patent pending applications to become patents, Huge for TSOI and for us
Huge up tick coming TSOI